Murizatoclax

Cat. No.:	HY-109184				
CAS No.:	2245848-05-7				
Molecular Formula:	C ₄₂ H ₅₇ ClN ₄ O ₅ S				
Molecular Weight:	765.44				
Target:	Bcl-2 Famil	у			
Pathway:	Apoptosis				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

®

MedChemExpress

SOLVENT & SOLUBILITY

		Mass			
Preparing Stock Solutions	Solvent Concentration	1 mg	5 mg	10 mg	
	1 mM	1.3064 mL	6.5322 mL	13.0644 mL	
	5 mM	0.2613 mL	1.3064 mL	2.6129 mL	
	10 mM	0.1306 mL	0.6532 mL	1.3064 mL	

Description	Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a K _i of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer ^{[1][2]} .	
IC ₅₀ & Target	MCL1 15 pM (Ki)	
In Vitro	AMG 397 potently disrupts the interaction between MCL1 and BIM in OPM2 cells, induces clear increases in Caspase-3/7 activity within one hour ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Murizatoclax (25-50 mg/kg; p.o. once or twice weekly) exhibits significant tumor regressions in mice bearing OPM2 xenografts ^[2] . Murizatoclax (10-60 mg/kg; p.o. twice weekly) achieves 47% MOLM-13 orthotopic tumor growth inhibition (TGI), 99% TGI and 75% regression at the dose of 10, 30 and 60 mg/kg, respectively ^[2] .	

0 0

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang H, et, al. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021 Apr 21;14(1):67.

[2]. Caenepeel S, et al. Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 2020;80(16 Supplement):6218.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA